Top

European Journal of Medical Research

Published in:

01-12-2011 | Research

Induction maintenance concept for HAART as initial treatment in HIV infected infants

Authors: S Ghosh, J Neubert, T Niehues, O Adams, N Morali-Karzei, A Borkhardt, HJ Laws

Published in: European Journal of Medical Research | Issue 6/2011

Abstract

Background

Early initiated antiretroviral therapy (ART) in HIV infected infants leads to improved long-term viral suppression and survival. Guidelines recommend initiating therapy with a triple ART consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) and either one additional non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). Compared to older children and adults, viral relapse is seen more frequently in infants receiving triple ART. We now address the possibility of a more potent ART with a quadruple induction and triple maintenance therapy.

Methods

We examine the longitudinal course in four HIV infected infants, who were referred from other centers and could not be recruited to multicentre trials. We introduced ART initially consisting of two NRTIs, one NNRTI and one PI and later discontinued the PI at the age of 12 months maintaining a triple regime consisting of two NRTIs and one NNRTI.

Results

Provided that therapy adherence was maintained we observed an effective sustained decline of viral load and significant CD4 cell reconstitution even after switching to a triple regime. No drug associated toxicity was seen.

Conclusion

We suggest that a four drug therapy might be a possible initial therapy option in HIV infected infants, at least in those with a high viral load, followed by a maintenance triple regime after 12 months of therapy.

Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, et al.: PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV medicine 2009,10(10):591–613.PubMedCrossRef

Children WGoATaMMoH-I: Guidelines for the Use of Antiretroviral Agents in Pediatric. HIV Infection 2009, 1–139.

Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al.: Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008,359(21):2233–44. 10.1056/NEJMoa0800971PubMedCentralPubMedCrossRef

Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al.: Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS (London, England) 2009,23(5):597–604. 10.1097/QAD.0b013e328326ca37CrossRef

PENPACT-1 First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. The Lancet infectious diseases. Jan 31

Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debre M, et al.: Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS (London, England) 2004,18(2):237–45.CrossRef

Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al.: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997,336(19):1337–42. 10.1056/NEJM199705083361901PubMedCrossRef

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, et al.: Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. Jama. 2006,296(7):769–81.PubMed

Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL: A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004,350(24):2471–80. 10.1056/NEJMoa032706PubMedCrossRef

10.

Melvin AJ, Lewis PF, Mohan KM, Naugler WS, Frenkel LM: Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children. Archives of pediatrics & adolescent medicine 2002,156(6):568–73.CrossRef

11.

Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, et al.: A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 2005,55(2):246–51. 10.1093/jac/dkh515PubMedCrossRef

12.

Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, et al.: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999,341(25):1874–81. 10.1056/NEJM199912163412502PubMedCrossRef

13.

Tudor-Williams G, Head S, Weigel R, Valerius NH, Ridell A, Lyall EG: Baby Cocktail! A protease-sparing 4 drug combination for symptomatic infants. International Conference on AIDS 2002, 14.

14.

DAIDS: National Institutes of Health, Division of AIDS Table for Grading the Severety of Adult and Pediatric Adverse Events, version 1.0. 2004.

15.

Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al.: Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clinical Immunol 2003,112(5):973–80. 10.1016/j.jaci.2003.07.003CrossRef

16.

Neubert J, Laws HJ, Adams O, Munk C, Kramer M, Niehues T, et al.: HIV-1 seroreversion following antiretroviral therapy in an HIV-infected child initially presenting with acquired immunodeficiency syndrome. AIDS (London, England) 24(2):327–8.

17.

Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, et al.: Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS (London, England) 2006,20(2):207–15. 10.1097/01.aids.0000200529.64113.3eCrossRef

18.

Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Bernardi S, et al.: Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC infectious diseases 2009, 9: 140. 10.1186/1471-2334-9-140PubMedCentralPubMedCrossRef

Title: Induction maintenance concept for HAART as initial treatment in HIV infected infants
Authors: S Ghosh
J Neubert
T Niehues
O Adams
N Morali-Karzei
A Borkhardt
HJ Laws
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 6/2011
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-16-6-243

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Induction maintenance concept for HAART as initial treatment in HIV infected infants

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2011

Management of pelvic lymphoceles after radical prostatectomy: A multicentre community based study

Dual endothelin-converting enzyme/neutral endopeptidase blockade in rats with D-galactosamine-induced liver failure

The non-invasive 13C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis

Immunohistochemical localization of notch signaling molecules in ameloblastomas

The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract

Comparative examination of subcutaneous tissue reaction to high molecular materials in medical use